



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PRTA

Last Trade:	46.03
Trade Time:	1:00 PM ET Nov 24, 2017
Change:	0.18 (+0.393%)
Day Range	45.40 - 46.42
52-Week Range	44.43 - 70.00
Volume	89,560

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 22, 2017 [Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)
- Nov 16, 2017 [Prothena Highlights Breadth of Novel Pipeline at R&D Day](#)
- Nov 7, 2017 [Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update](#)
- Nov 1, 2017 [Prothena to Participate in the Credit Suisse 26th Annual Healthcare Conference](#)
- Oct 31, 2017 [Prothena to Report Third Quarter 2017 Financial Results on November 7](#)

Upcoming Events [\[View all \]](#)

- Nov 30, 2017 1:15 PM ET [Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 27, 2017 [Annual Report \(10-K\)](#)
- Mar 31, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 9, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)